Andrew K. Balo Sells 5,000 Shares of DexCom Inc. (DXCM) Stock
DexCom Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of DexCom stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $82.55, for a total transaction of $412,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Andrew K. Balo also recently made the following trade(s):
- On Wednesday, September 21st, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $92.87, for a total transaction of $464,350.00.
DexCom Inc. (NASDAQ:DXCM) opened at 82.93 on Friday. The firm’s market cap is $6.96 billion. DexCom Inc. has a 1-year low of $47.92 and a 1-year high of $96.38. The stock’s 50 day moving average price is $90.88 and its 200 day moving average price is $77.91.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/andrew-k-balo-sells-5000-shares-of-dexcom-inc-dxcm-stock.html
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.12. The firm had revenue of $137.30 million for the quarter, compared to analyst estimates of $132.48 million. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The business’s revenue was up 47.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) earnings per share. Equities research analysts predict that DexCom Inc. will post ($0.57) EPS for the current year.
A number of large investors have recently modified their holdings of DXCM. Aperio Group LLC raised its stake in shares of DexCom by 100.8% in the first quarter. Aperio Group LLC now owns 6,633 shares of the medical device company’s stock valued at $450,000 after buying an additional 3,330 shares in the last quarter. Pacad Investment Ltd. raised its stake in shares of DexCom by 152.9% in the first quarter. Pacad Investment Ltd. now owns 10,300 shares of the medical device company’s stock valued at $699,000 after buying an additional 6,228 shares in the last quarter. Teachers Advisors Inc. raised its stake in shares of DexCom by 6.9% in the first quarter. Teachers Advisors Inc. now owns 174,684 shares of the medical device company’s stock valued at $11,863,000 after buying an additional 11,291 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of DexCom by 37.9% in the first quarter. Prudential Financial Inc. now owns 138,269 shares of the medical device company’s stock valued at $9,390,000 after buying an additional 38,032 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of DexCom by 7.7% in the first quarter. Franklin Resources Inc. now owns 1,476,904 shares of the medical device company’s stock valued at $100,296,000 after buying an additional 106,215 shares in the last quarter. 99.37% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently weighed in on DXCM shares. Wedbush reiterated an “outperform” rating and issued a $112.00 price objective on shares of DexCom in a research report on Wednesday, June 15th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of DexCom in a research report on Monday, June 20th. Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, June 28th. Canaccord Genuity reiterated a “buy” rating and issued a $95.00 price objective on shares of DexCom in a research report on Wednesday, July 13th. Finally, Jefferies Group reiterated a “buy” rating and issued a $98.00 price objective (up from $90.00) on shares of DexCom in a research report on Friday, July 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. DexCom currently has a consensus rating of “Buy” and a consensus price target of $95.08.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.